Application of programmed death 1 inhibitors in Hodgkin lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 449-454, 2021.
Artigo
em Chinês
| WPRIM
| ID: wpr-907198
ABSTRACT
The programmed death-1 (PD-1) inhibitor has a unique mechanism and better efficacy in classic Hodgkin lymphoma (cHL). Multiple PD-1 inhibitors have been approved for the salvage treatment of patients with cHL in advanced stage. The combination of PD-1 with other small molecule targeted drugs, immunoactive drugs or cytotoxic drugs can further improve the efficacy and have a better safety compared with the traditional treatment, meanwhile, the regimens have also been explored in treatment of recurrent and refractory patients and frontline therapy. In addition, 9P24.1 amplification, PD-1 ligand expression and circulating tumor DNA level may be potential biomarkers for predicting the efficacy of PD-1 inhibitors.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2021
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS